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disorder appears to exceed 415,000 [31,905 x (2.75/35%)] + [17,000 x (3.4/35%)]. 
On average, 1.5 work days are lost by staff following patient assault at an annual cost 
of $444.4 million (based on hourly pay rates for nurses and doctors of $41 and $162, 
respectively). CONCLUSIONS: Rapid and effective de-escalation of agitation among 
patients with schizophrenia or bipolar disorder seeking care in the ED may reduce the 
incidence and associated costs of staff assaults.
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OBJECTIVES: The aim of this research was to evaluate patient characteristics, length 
of stay (LOS), and costs among children and adolescents hospitalized in the United 
States (US) for ADHD. METHODS: The study used data from 2000–2006 in the 
Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS). 
Patients included were children (6–11 years old) and adolescents (12–17 years old) 
that were hospitalized with a primary diagnosis of ADHD (ICD-9-CM 314.00 or 
314.01). Data collected includes age, gender, race, payer type, admission source, 
admission type, geographic region, hospital status, year admitted, mean LOS and 
mean costs. RESULTS: Among children, 28,247 patients met inclusion criteria and 
83.74% were male. Medicaid was the most common form of health insurance 
(68.97%) followed by private insurance (26.67%). The majority of patients were 
hospitalized in urban locations (96.69%) and were admitted from the emergency room 
(33.75%). Mean (SE) LOS was 10.76 days (0.85) and mean (SE) costs were $10,106 
($1,358). Among adolescents, 21,612 patients met inclusion criteria and 75.70% were 
male. Medicaid was the most common form of health insurance (57.38%) followed 
by private insurance (36.99%). The majority of patients were hospitalized in urban 
locations (93.83%) and admitted from the emergency room (38.77%). Mean (SE) 
LOS was 8.66 days (0.66) and mean (SE) costs were $7886 ($1387). The number of 
hospitalizations for ADHD in each individual year from 2000–2006 was fairly con-
stant for both children and adolescents. CONCLUSIONS: Children and adolescents 
hospitalized for ADHD carry a substantial economic burden to the US health care 
system. The majority of these patients are male, come from urban locations and have 
Medicaid as their primary form of health insurance. Health care decision makers 
should be aware of the burden of ADHD in these populations. Research evaluating 
the impact of behavioural and/or pharmalogical ADHD treatment on hospitalizations 
should be explored.
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OBJECTIVES: Estimate the current societal costs of opioid abuse, dependence, and 
misuse. METHODS: Costs associated with opioid abuse were grouped into three 
major categories: health care, workplace, and criminal justice. Two general principles 
were adopted to estimate costs: 1) a quantity method, which multiplies the number 
of opioid abuse patients by the estimated cost per opioid abuse patient, and, 2) an 
apportionment method, which begins with the overall costs of drug abuse for a cost 
component and apportions the share associated with opioid abuse based on the rela-
tive prevalence of opioid abuse to overall drug abuse. Excess health care costs per 
patient were based on analysis of two claims datasets: a privately-insured population 
and Florida Medicaid. Other data/information was derived from publicly-available 
secondary resources (e.g., academic research, government reports and surveys). 
RESULTS: Total societal costs of opioid abuse in the U.S. were estimated at $54.5 
billion annually (2008 dollars). Disaggregated by major category, workplace costs 
accounted for $25.1 billion (46%), health care costs accounted for $24.2 billion 
(44%), and criminal justice costs accounted for $5.2 billion (10%). Workplace costs 
were driven by lost earnings due to premature death ($11.1 billion) and reduced 
compensation/lost employment associated with opioid abuse ($7.8 billion). Health 
care costs consisted primarily of excess medical and prescription drug costs for opioid 
abuse patients ($23.0 billion). Criminal justice costs were largely made up of cor-
rectional facility costs attributable to opioid abuse ($2.3 billion) and police protection 
costs attributable to opioid abuse ($1.5 billion). CONCLUSIONS: The costs of opioid 
abuse represent a substantial and growing economic burden for society in the U.S. 
The increasing prevalence of abuse and related spending suggest an even greater 
societal burden in the future. Recent initiatives developed by the government, clini-
cians, and the health care industry may help reduce the burden of opioid abuse.
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OBJECTIVES: Compare health care costs of patients with post-traumatic stress dis-
order (PTSD) to those of patients with major depressive disorder (MDD) in U.S. 
Medicaid and privately-insured populations. METHODS: Patients with ≥2 PTSD 
diagnoses (ICD-9-CM: 309.81) on/after January 1, 1999 and ≥1 PTSD diagnosis on/
after January 1, 2003 were identiﬁed from Medicaid claims data from Florida, 
Missouri, and New Jersey (1999–2007) and from a privately-insured claims database 
(1999–2008). The index date was deﬁned as the ﬁrst PTSD diagnosis on/after 1/1/2003 
that was not the ﬁrst overall PTSD diagnosis. PTSD patients had continuous eligibility 
for the 6-month baseline period before and 12-month study period following their 
index date and were ages 18–64 during the study period. Potential MDD controls 
(ICD-9-CM: 296.2, 296.3) without PTSD diagnosis were identiﬁed using similar 
selection criteria. MDD controls were matched to PTSD patients on age, gender, 
state/region, employment status, index year, and race (for Medicaid patients). 
Study period direct costs, calculated as reimbursements in 2008 dollars to third-party 
payers for medical services and prescription drugs, were compared between PTSD 
patients and matched MDD controls using nonparametric bootstrapping. RESULTS: 
In the baseline period, PTSD patients had higher rates of other mental disorders 
(e.g. anxiety, bipolar disorder), and higher average direct costs than MDD controls 
both in the Medicaid and privately-insured populations. Among Medicaid patients, 
PTSD patients also had lower average Charlson Comorbidity Index compared 
with MDD controls. Average study period direct costs were higher for PTSD patients 
than MDD controls ($18,753 vs. $17,990 for Medicaid and $10,960 vs. $10,024 for 
privately-insured, both p < 0.05). The difference in direct costs was driven by higher 
mental health-related costs for PTSD patients than for MDD controls. CONCLU-
SIONS: PTSD patients had approximately 4–10% higher direct costs in the 12-month 
study period compared to MDD controls driven by higher mental-health related direct 
costs.
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OBJECTIVES: To examine patterns of health care utilization and costs in patients 
with generalized anxiety disorder (GAD) beginning treatment with benzodiazepine 
anxiolytics as add-on therapy to selective serotonin reuptake inhibitors (SSRI) or 
venlafaxine. METHODS: Using a large US health insurance claims database, we 
identiﬁed all persons with evidence of GAD (ICD-9-CM diagnosis code 300.02) who 
were receiving treatment (≥90 days) with SSRIs or venlafaxine between January 1, 
2003 and December 31, 2007. Among these patients, we then selected those who 
began add-on therapy with a benzodiazepine anxiolytic. Designating the date of initial 
receipt of a benzodiazepine the “index date”, we compiled all health care claims over 
the 6-month period preceding this date (“pre-index”) and the 12-month period fol-
lowing it (“follow-up”). Patients with incomplete data were excluded. Health care 
utilization and costs were then examined during these periods. RESULTS: A total of 
2131 patients met all study inclusion criteria. Mean age was 43 years; 73% were 
women. Patients averaged 32 days of therapy with benzodiazepines, however, dura-
tion of therapy was >90 days, for 14% of patients. In general, levels of health care 
utilization during the ﬁrst 6 months of follow-up were higher than during pre-index; 
during the second 6 months of follow-up, however, they were somewhat lower than 
pre-index. Median (IQR) total health care costs were $2672 ($1465-$4960) during 
pre-index, $2897 ($1525–5663) during the ﬁrst 6 months of follow-up, and $2581 
($1270-$5107) during the second 6 months of follow-up. CONCLUSIONS: Overall 
health care utilization and associated costs increased following initial GAD diagnosis. 
Although the duration of treatment is typically brief, some patients receive benzodi-
azepine anxiolytics as add-on therapy to SSRIs or venlafaxine for periods longer than 
90 days, which is not recommended due to risks of dependency and sedation.
PMH41
THE SOCIETAL COST OF SCHIZOPHRENIA IN SWEDEN
Ekman M1, Granström O2, Omerov S3, Jacob J2, Landén M4
1i3 Innovus, Stockholm, Sweden, 2AstraZeneca Nordic MC, Södertälje, Sweden, 3Northern 
Stockholm Psychiatry, Stockholm, Sweden, 4Gothenburg University, Göteborg, Sweden
OBJECTIVES: To investigate the health care resource utilization and cost-of-illness 
in patients with schizophrenia in Sweden. METHODS: Data on socio-demographics 
and disease-related health care resource use for 2412 patients were collected using 
registry data for the period 2006–2008. Data on health care visits and inpatient days 
were obtained from the Northern Stockholm psychiatric clinic, while data on phar-
maceuticals, sick leave and early retirement were obtained from the national pharma-
ceutical registry and the Swedish social insurance agency, respectively. Costs for 
community care were not available on individual level in the databases, and were 
therefore obtained from previous studies. The study was conducted from a societal 
perspective, with indirect costs valued according to the human capital method. 
RESULTS: The average annual cost per patient with schizophrenia in the period 
2006–2008 was estimated at 348,300o (US$68,800) in 2009 prices. Total costs 
increased by 8% from 2006 to 2008, mainly because of increased indirect costs. 
Outpatient care represented 5%, inpatient care 9%, pharmaceuticals 3%, community 
care 24% and productivity losses 59% of total costs. Costs (excluding community 
care cost, which was not available on the individual level) were signiﬁcantly and posi-
tively correlated with lower functioning as assessed with GAF (General Assessment of 
Functioning). Costs in the lowest GAF class (GAF < 50) were almost three times as 
large as in the highest GAF class (GAF > = 70). Men had signiﬁcantly higher indirect 
